Loading
A phase 3 trial of Pilocarpine in Head and neck squamous cell carcinoma, run by Radiation Therapy Oncology Group, completed.
Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck Cancer is a phase 3 interventional study registered as NCT00003139 by Radiation Therapy Oncology Group, with 249 participants recorded, started 1998-03 and reaching its primary completion in 2001-01. Interventions recorded: pilocarpine hydrochloride, Placebo. Conditions recorded: Head and Neck Cancer, Oral Complications.
Linked to the drug Pilocarpine because the registry names it among its interventions and Head and neck squamous cell carcinoma among its conditions. Registry record only: no result has been read by an editor.
Shares Pilocarpine, Head and neck squamous cell carcinoma and the tag pipeline.
Shares Oral cavity cancer (mouth and tongue), NRG Oncology and the tag pipeline.
Shares Pilocarpine and the tag pipeline.
Shares Oral cavity cancer (mouth and tongue), Head and neck squamous cell carcinoma and the tag pipeline.
Shares Oral cavity cancer (mouth and tongue), Head and neck squamous cell carcinoma and the tag pipeline.
Shares Oral cavity cancer (mouth and tongue), Head and neck squamous cell carcinoma and the tag pipeline.
Shares Oral cavity cancer (mouth and tongue), Head and neck squamous cell carcinoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma and the tag pipeline.